person · Reporting owner

Hedley Mary Lynne

Disclosed activity across 6 companies

Tapewire entity: 2125
SEC CIK: 0001340823

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ELI LILLY & CoLLY · Entity 2794	Director	December 15, 2025	December 16, 2025
Tempest Therapeutics, Inc.MLND · Entity 7734	Director	June 22, 2020	June 23, 2020
VEEVA SYSTEMS INCVEEV · Entity 2124	Director	September 01, 2026	September 03, 2026
bluebird bio, Inc.BLUE · Entity 78923	Director	June 20, 2018	June 22, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ELI LILLY & Co

Report date December 15, 2025 · Filed December 16, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,252.694	Reported balance After 2025-12-15 transaction · row 1 1 source row Row 1 · 2025-12-15 · Grant · Acquired 9.336 · Balance 2,252.694 F1: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.
Common StockSEC Table I · non-derivative	IndirectBy Trust	98	Reported balance Holding disclosure · report date 2025-12-15 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 98 F2: The reporting person disclaims beneficial ownership of the reported securities except to the extent of the reporting person's pecuniary interest therein, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.

F2: The reporting person disclaims beneficial ownership of the reported securities except to the extent of the reporting person's pecuniary interest therein, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Tempest Therapeutics, Inc.

Report date June 22, 2020 · Filed June 23, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2030-06-21	Direct	12,000	Reported balance After 2020-06-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-06-22 · Grant · Acquired 12,000 · Balance 12,000 F1: One hundred percent (100%) of the shares subject to this option will vest on the earlier of (1) June 22, 2021 and (2) the date of the first Annual Meeting following the grant date, subject to the Reporting Person continuing to provide service to the Issuer through such date.

Filing footnotes · ownership attribution and instrument terms

F1: One hundred percent (100%) of the shares subject to this option will vest on the earlier of (1) June 22, 2021 and (2) the date of the first Annual Meeting following the grant date, subject to the Reporting Person continuing to provide service to the Issuer through such date.

VEEVA SYSTEMS INC

Report date September 01, 2026 · Filed September 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	7,629	Reported balance After 2026-09-01 transaction · row 1 1 source row Row 1 · 2026-09-01 · Exercise / conversion · Acquired 477 · Balance 7,629 F1: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	1,429	Reported balance After 2026-09-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-09-01 · Exercise / conversion · Disposed 477 · Balance 1,429 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3: On June 17, 2026, the Reporting Person was granted 1,906 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2026, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act.

F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer.

F3: On June 17, 2026, the Reporting Person was granted 1,906 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2026, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date.

bluebird bio, Inc.

Report date June 20, 2018 · Filed June 22, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,700	Reported balance After 2018-06-20 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2018-06-20 · Grant · Acquired 1,000 · Balance 3,700 F1: These restricted stock units for common stock vest 100% on the earlier of June 20, 2019 or the date of the next annual meeting of stockholders.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $183.10 · Expires 2028-06-20	Direct	4,000	Reported balance After 2018-06-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-06-20 · Grant · Acquired 4,000 · Balance 4,000 F2: This option vests 100% on the earlier of June 20, 2019 or the date of the next annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: These restricted stock units for common stock vest 100% on the earlier of June 20, 2019 or the date of the next annual meeting of stockholders.

F2: This option vests 100% on the earlier of June 20, 2019 or the date of the next annual meeting of stockholders.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Centessa Pharmaceuticals plc

Report date June 24, 2026 · Filed June 24, 2026

Section 16 reporting ended · disclosed 2026-06-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.84 · Expires 2031-02-19	Direct	Reported balance After 2026-06-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-24 · Disposition to issuer · Disposed 208,474 · Balance 0 F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement"). F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.87 · Expires 2032-06-30	Direct	Reported balance After 2026-06-24 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-24 · Disposition to issuer · Disposed 48,000 · Balance 0 F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement"). F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.35 · Expires 2033-06-22	Direct	Reported balance After 2026-06-24 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-24 · Disposition to issuer · Disposed 48,000 · Balance 0 F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement"). F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.89 · Expires 2034-06-25	Direct	Reported balance After 2026-06-24 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-06-24 · Disposition to issuer · Disposed 48,000 · Balance 0 F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement"). F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.43 · Expires 2035-06-20	Direct	Reported balance After 2026-06-24 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-06-24 · Disposition to issuer · Disposed 40,000 · Balance 0 F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement"). F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Filing footnotes · ownership attribution and instrument terms

F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement").

F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time.

F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

TESARO, Inc.

Report date January 22, 2019 · Filed January 22, 2019

Section 16 reporting ended · disclosed 2019-01-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-01-22 transaction · row 1 1 source row Row 1 · 2019-01-22 · Other · Disposed 26,816 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement").
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2019-01-22 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2019-01-22 · Other · Disposed 563,569 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). F2: These shares are held by trusts of which the Reporting Person is a trustee or co-trustee. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, of such portion of the shares of TESARO held by the trusts in which the Reporting Person has no pecuniary interest.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2019-01-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-01-22 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F4: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2019-01-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-01-22 · Disposition to issuer · Disposed 8,339 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F4: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2019-01-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-01-22 · Disposition to issuer · Disposed 40,909 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F4: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.33 · Expires 2021-07-19	Direct	Reported balance After 2019-01-22 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-01-22 · Disposition to issuer · Disposed 285,714 · Balance 0 F5: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.62 · Expires 2022-03-16	Direct	Reported balance After 2019-01-22 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-01-22 · Disposition to issuer · Disposed 319,467 · Balance 0 F5: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.18 · Expires 2023-03-06	Direct	Reported balance After 2019-01-22 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-01-22 · Disposition to issuer · Disposed 175,000 · Balance 0 F5: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.74 · Expires 2024-02-27	Direct	Reported balance After 2019-01-22 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2019-01-22 · Disposition to issuer · Disposed 105,000 · Balance 0 F5: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.11 · Expires 2025-03-06	Direct	Reported balance After 2019-01-22 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2019-01-22 · Disposition to issuer · Disposed 115,000 · Balance 0 F5: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.39 · Expires 2026-03-01	Direct	Reported balance After 2019-01-22 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2019-01-22 · Disposition to issuer · Disposed 80,000 · Balance 0 F5: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $178.95 · Expires 2027-03-01	Direct	Reported balance After 2019-01-22 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2019-01-22 · Disposition to issuer · Disposed 20,216 · Balance 0 F4: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F6: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.84 · Expires 2028-03-01	Direct	Reported balance After 2019-01-22 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2019-01-22 · Disposition to issuer · Disposed 71,896 · Balance 0 F5: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.

Filing footnotes · ownership attribution and instrument terms

F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement").

F2: These shares are held by trusts of which the Reporting Person is a trustee or co-trustee. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, of such portion of the shares of TESARO held by the trusts in which the Reporting Person has no pecuniary interest.

F3: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock.

F4: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.

F5: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]

F6: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 01, 2024 Filed Jun 3, 2024 21:09 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	Exercise / conversionClass A Common Stock	302	$0.00	$0.00	Disclosure SEC source: 0001628280-24-026410 · wk-form4_1717448969.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. Read SEC document
May 20, 2024 Filed May 21, 2024 20:19 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	13	$783.18	$10,181.34	Disclosure SEC source: 0000059478-24-000131 · wk-form4_1716322774.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,490 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
April 15, 2024 Filed Apr 16, 2024 20:11 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	13	$750.77	$9,760.01	Disclosure SEC source: 0000059478-24-000105 · wk-form4_1713298290.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,477 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
March 18, 2024 Filed Mar 19, 2024 20:17 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	13	$762.66	$9,914.58	Disclosure SEC source: 0000059478-24-000086 · wk-form4_1710879436.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,464 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
March 01, 2024 Filed Mar 5, 2024 19:22 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	Exercise / conversionRestricted Stock Units · Derivative	302	$0.00	$0.00	Disclosure SEC source: 0001628280-24-008835 · wk-form4_1709666556.xml · derivative · entry 2 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 302 Underlying: Class A Common Stock · 302 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 21, 2023, the Reporting Person was granted 1,209 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2023, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 21, 2023, the Reporting Person was granted 1,209 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2023, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document
March 01, 2024 Filed Mar 5, 2024 19:22 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	Exercise / conversionClass A Common Stock	302	$0.00	$0.00	Disclosure SEC source: 0001628280-24-008835 · wk-form4_1709666556.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. Read SEC document
February 20, 2024 Filed Feb 21, 2024 21:24 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	13	$755.66	$9,823.58	Disclosure SEC source: 0000059478-24-000073 · wk-form4_1708550604.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,449 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
January 16, 2024 Filed Jan 17, 2024 21:14 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	16	$634.57	$10,153.12	Disclosure SEC source: 0000059478-24-000004 · wk-form4_1705526038.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,437 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
December 28, 2023 Filed Dec 28, 2023 22:24 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	SaleClass A Common Stock	42	$191.07	$8,024.94	Disclosure SEC source: 0001628280-23-042823 · wk-form4_1703802280.xml · nonDerivative · entry 2 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,128 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 27, 2023. Read SEC document
December 27, 2023 Filed Dec 28, 2023 22:24 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	SaleClass A Common Stock	41	$190.96	$7,829.36	Disclosure SEC source: 0001628280-23-042823 · wk-form4_1703802280.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,170 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 27, 2023. Read SEC document
December 18, 2023 Filed Dec 19, 2023 21:12 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	17	$579.76	$9,855.92	Disclosure SEC source: 0000059478-23-000322 · wk-form4_1703020305.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,421 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
December 01, 2023 Filed Dec 2, 2023 00:01 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	Exercise / conversionRestricted Stock Units · Derivative	303	$0.00	$0.00	Disclosure SEC source: 0001628280-23-040504 · wk-form4_1701475259.xml · derivative · entry 2 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 604 Underlying: Class A Common Stock · 303 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 21, 2023, the Reporting Person was granted 1,209 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2023, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 21, 2023, the Reporting Person was granted 1,209 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2023, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document
December 01, 2023 Filed Dec 2, 2023 00:01 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	Exercise / conversionClass A Common Stock	303	$0.00	$0.00	Disclosure SEC source: 0001628280-23-040504 · wk-form4_1701475259.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. Read SEC document
November 20, 2023 Filed Nov 21, 2023 21:20 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	335	$597.60	$200,196.00	Disclosure SEC source: 0000059478-23-000300 · wk-form4_1700601640.xml · nonDerivative · entry 2 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,403 Read SEC document
November 20, 2023 Filed Nov 21, 2023 21:20 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	17	$597.60	$10,159.20	Disclosure SEC source: 0000059478-23-000300 · wk-form4_1700601640.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,068 F1 · shares: At the election of the reporting person, the shares acquired in this row have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
October 16, 2023 Filed Oct 17, 2023 20:19 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	16	$616.64	$9,866.24	Disclosure SEC source: 0000059478-23-000270 · wk-form4_1697573978.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,051 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
September 18, 2023 Filed Sep 20, 2023 20:25 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	17	$571.28	$9,711.76	Disclosure SEC source: 0000059478-23-000255 · wk-form4_1695241528.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,035 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
September 01, 2023 Filed Sep 5, 2023 23:53 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	Exercise / conversionRestricted Stock Units · Derivative	302	$0.00	$0.00	Disclosure SEC source: 0001628280-23-031452 · wk-form4_1693958013.xml · derivative · entry 2 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 907 Underlying: Class A Common Stock · 302 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 21, 2023, the Reporting Person was granted 1,209 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2023, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 21, 2023, the Reporting Person was granted 1,209 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2023, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document
September 01, 2023 Filed Sep 5, 2023 23:53 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	Exercise / conversionClass A Common Stock	302	$0.00	$0.00	Disclosure SEC source: 0001628280-23-031452 · wk-form4_1693958013.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,908 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. Read SEC document
August 21, 2023 Filed Aug 22, 2023 20:28 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	18	$550.50	$9,909.00	Disclosure SEC source: 0000059478-23-000231 · wk-form4_1692736074.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,017 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
July 17, 2023 Filed Jul 18, 2023 20:36 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	22	$447.14	$9,837.08	Disclosure SEC source: 0000059478-23-000211 · wk-form4_1689712598.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 999 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
July 13, 2023 Filed Jul 13, 2023 22:58 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	SaleClass A Common Stock	138	$208.31	$28,746.78	Disclosure SEC source: 0001628280-23-024870 · wf-form4_168928909905987.xml · nonDerivative · entry 2 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,606 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting person on April 13, 2023. Read SEC document
July 12, 2023 Filed Jul 13, 2023 22:58 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	SaleClass A Common Stock	92	$207.20	$19,062.40	Disclosure SEC source: 0001628280-23-024870 · wf-form4_168928909905987.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,744 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting person on April 13, 2023. Read SEC document
June 22, 2023 Filed Jun 23, 2023 21:03 UTC	Centessa Pharmaceuticals plc CNTA · Entity 35581	GrantShare Option (right to buy) · Derivative	48,000	$0.00 Strike: $6.35	$0.00	Disclosure SEC source: 0001847903-23-000126 · wf-form4_168755421969730.xml · derivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,000 Underlying: Ordinary Shares · 48,000 shares Expires 2033-06-22 F1 · derivative.exercise_date: The shares subject to such option will vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's next annual meeting of shareholders, subject to continued service as a director through the applicable vesting date. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 21, 2023 Filed Jun 23, 2023 18:41 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	GrantRestricted Stock Units · Derivative	1,209	$0.00	$0.00	Disclosure SEC source: 0001628280-23-023269 · wk-form4_1687545658.xml · derivative · entry 2 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,209 Underlying: Class A Common Stock · 1,209 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F2 · derivative.exercise_date: The RSUs were granted under the Issuer's Amended & Restated 2013 Equity Incentive Plan. The Reporting Person vests ownership in the RSUs over one year with 1/4 of the RSUs vesting on September 1, 2023, and 1/4 of the RSUs vesting on a quarterly basis thereafter, subject to continued service to the Issuer by the Reporting Person. F2 · derivative.expiration_date: The RSUs were granted under the Issuer's Amended & Restated 2013 Equity Incentive Plan. The Reporting Person vests ownership in the RSUs over one year with 1/4 of the RSUs vesting on September 1, 2023, and 1/4 of the RSUs vesting on a quarterly basis thereafter, subject to continued service to the Issuer by the Reporting Person. Read SEC document
June 20, 2023 Filed Jun 21, 2023 20:22 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	22	$451.95	$9,942.90	Disclosure SEC source: 0000059478-23-000194 · wk-form4_1687378943.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 977 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
June 01, 2023 Filed Jun 5, 2023 21:16 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	Exercise / conversionRestricted Stock Units · Derivative	326	$0.00	$0.00	Disclosure SEC source: 0001628280-23-020910 · wk-form4_1685999797.xml · derivative · entry 2 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 326 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 9, 2022, the Reporting Person was granted 1,306 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2022, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 9, 2022, the Reporting Person was granted 1,306 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2022, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document
June 01, 2023 Filed Jun 5, 2023 21:16 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	Exercise / conversionClass A Common Stock	326	$0.00	$0.00	Disclosure SEC source: 0001628280-23-020910 · wk-form4_1685999797.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. Read SEC document
May 15, 2023 Filed May 16, 2023 20:24 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	23	$434.51	$9,993.73	Disclosure SEC source: 0000059478-23-000174 · wf-form4_168426865232884.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 953 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
April 17, 2023 Filed Apr 19, 2023 20:29 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	27	$372.35	$10,053.45	Disclosure SEC source: 0000059478-23-000148 · wf-form4_168193613806276.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 930 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
March 20, 2023 Filed Mar 22, 2023 20:10 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	30	$333.60	$10,008.00	Disclosure SEC source: 0000059478-23-000129 · wf-form4_167951581609755.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 655 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
March 01, 2023 Filed Mar 3, 2023 20:35 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	Exercise / conversionRestricted Stock Units · Derivative	327	$0.00	$0.00	Disclosure SEC source: 0001628280-23-006257 · wf-form4_167787572075017.xml · derivative · entry 2 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326 Underlying: Class A Common Stock · 327 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 9, 2022, the Reporting Person was granted 1,306 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2022, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 9, 2022, the Reporting Person was granted 1,306 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2022, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document
March 01, 2023 Filed Mar 3, 2023 20:35 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	Exercise / conversionClass A Common Stock	327	$0.00	$0.00	Disclosure SEC source: 0001628280-23-006257 · wf-form4_167787572075017.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. Read SEC document
February 21, 2023 Filed Feb 22, 2023 21:53 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	30	$327.51	$9,825.30	Disclosure SEC source: 0000059478-23-000090 · wf-form4_167710278960618.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 623 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
January 17, 2023 Filed Jan 19, 2023 21:39 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	28	$357.74	$10,016.72	Disclosure SEC source: 0000059478-23-000008 · wf-form4_167416436661581.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 593 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
December 19, 2022 Filed Dec 20, 2022 22:11 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	28	$357.78	$10,017.84	Disclosure SEC source: 0000059478-22-000283 · wf-form4_167157425145374.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 565 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
December 01, 2022 Filed Dec 5, 2022 23:22 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	Exercise / conversionRestricted Stock Units · Derivative	326	$0.00	$0.00	Disclosure SEC source: 0001628280-22-031392 · wf-form4_167028253089664.xml · derivative · entry 2 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 653 Underlying: Class A Common Stock · 326 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 9, 2022, the Reporting Person was granted 1,306 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2022, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 9, 2022, the Reporting Person was granted 1,306 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2022, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document
December 01, 2022 Filed Dec 5, 2022 23:22 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	Exercise / conversionClass A Common Stock	326	$0.00	$0.00	Disclosure SEC source: 0001628280-22-031392 · wf-form4_167028253089664.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. Read SEC document
November 21, 2022 Filed Nov 22, 2022 22:33 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	332	$361.17	$119,908.44	Disclosure SEC source: 0000059478-22-000267 · wf-form4_166915637324950.xml · nonDerivative · entry 2 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 536 Read SEC document
November 21, 2022 Filed Nov 22, 2022 22:33 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	27	$361.17	$9,751.59	Disclosure SEC source: 0000059478-22-000267 · wf-form4_166915637324950.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
October 17, 2022 Filed Oct 19, 2022 20:14 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	30	$332.76	$9,982.80	Disclosure SEC source: 0000059478-22-000239 · wf-form4_166621045570353.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
September 19, 2022 Filed Sep 21, 2022 20:35 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	33	$305.09	$10,067.97	Disclosure SEC source: 0000059478-22-000223 · wf-form4_166379254190858.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
September 01, 2022 Filed Sep 6, 2022 23:39 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	Exercise / conversionRestricted Stock Units · Derivative	327	$0.00	$0.00	Disclosure SEC source: 0001628280-22-024425 · wf-form4_166250758253020.xml · derivative · entry 2 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 979 Underlying: Class A Common Stock · 327 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 9, 2022, the Reporting Person was granted 1,306 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2022, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 9, 2022, the Reporting Person was granted 1,306 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2022, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document
September 01, 2022 Filed Sep 6, 2022 23:39 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	Exercise / conversionClass A Common Stock	327	$0.00	$0.00	Disclosure SEC source: 0001628280-22-024425 · wf-form4_166250758253020.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,857 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. Read SEC document
August 15, 2022 Filed Aug 16, 2022 20:17 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	32	$313.94	$10,046.08	Disclosure SEC source: 0000059478-22-000207 · wf-form4_166068106178799.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
July 18, 2022 Filed Jul 20, 2022 00:10 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	31	$321.77	$9,974.87	Disclosure SEC source: 0000059478-22-000190 · wf-form4_165827583473559.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
June 30, 2022 Filed Jul 5, 2022 23:00 UTC	Centessa Pharmaceuticals plc CNTA · Entity 35581	GrantShare Option (right to buy) · Derivative	48,000	$0.00 Strike: $4.87	$0.00	Disclosure SEC source: 0000899243-22-025104 · doc4.xml · derivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Underlying: Ordinary Shares · 48,000 shares Expires 2032-06-30 F1 · derivative.exercise_date: The shares subject to such option will vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's next annual meeting of shareholders, subject to continued service as a director through the applicable vesting date. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 21, 2022 Filed Jun 22, 2022 21:34 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	33	$297.34	$9,812.22	Disclosure SEC source: 0000059478-22-000167 · wf-form4_165593366397520.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
June 09, 2022 Filed Jun 14, 2022 01:30 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	GrantRestricted Stock Units · Derivative	1,306	$0.00	$0.00	Disclosure SEC source: 0001628280-22-016995 · wf-form4_165517018212202.xml · derivative · entry 2 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,306 Underlying: Class A Common Stock · 1,306 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F2 · derivative.exercise_date: The RSUs were granted under the Issuer's Amended & Restated 2013 Equity Incentive Plan. The Reporting Person vests ownership in the RSUs over one year with 1/4 of the RSUs vesting on September 1, 2022, and 1/4 of the RSUs vesting on a quarterly basis thereafter, subject to continued service to the Issuer by the Reporting Person. F2 · derivative.expiration_date: The RSUs were granted under the Issuer's Amended & Restated 2013 Equity Incentive Plan. The Reporting Person vests ownership in the RSUs over one year with 1/4 of the RSUs vesting on September 1, 2022, and 1/4 of the RSUs vesting on a quarterly basis thereafter, subject to continued service to the Issuer by the Reporting Person. Read SEC document
June 01, 2022 Filed Jun 2, 2022 23:47 UTC	VEEVA SYSTEMS INC VEEV · Entity 2124	Exercise / conversionRestricted Stock Units · Derivative	197	$0.00	$0.00	Disclosure SEC source: 0001628280-22-016101 · wf-form4_165421361819340.xml · derivative · entry 2 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 197 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · date: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under theAct. F3 · derivative.exercise_date: On June 23, 2021, the Reporting Person was granted 788 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2021, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 23, 2021, the Reporting Person was granted 788 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2021, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.